← All Kronos Bio, INC filings

Kronos Bio, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

KRON
Kronos Bio, INC
10-K/A: Kronos Bio Files Amendment to 10-K to Include Part III Information
Kronos Bio files an amendment to its 2024 Form 10-K to include Part III information regarding directors, executive officers, compensation, and related matters.
KRON
Kronos Bio, INC
10-K: Kronos Bio Announces Strategic Review and Reports 2024 Financial Results
Kronos Bio discontinues istisociclib development, initiates strategic review, and reports a net loss of $86.1 million for 2024.
KRON
Kronos Bio, INC
10-K: Kronos Bio Announces Executive Separation Agreements and Details Severance Packages
Kronos Bio has entered into separation agreements with two executive officers, outlining severance benefits including payments, healthcare continuation, and equity acceleration.